Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin
about
Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice?Clinical relevance of genetic polymorphisms in the human CYP2C subfamilyPhenotype-genotype analysis of CYP2C19 in Colombian mestizo individuals.CYP2C19 genetic variants affect nelfinavir pharmacokinetics and virologic response in HIV-1-infected children receiving highly active antiretroviral therapy.Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populationsPharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19.Comparison of (S)-mephenytoin and proguanil oxidation in vitro: contribution of several CYP isoforms.Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease.Molecular mechanisms of genetic variation and transcriptional regulation of CYP2C19.Novel variants of major drug-metabolising enzyme genes in diverse African populations and their predicted functional effects.Clinical Application of CYP2C19 Pharmacogenetics Toward More Personalized MedicineGenetic polymorphism of (S)-mephenytoin 4'-hydroxylation in populations of African descent.Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine.The effects of cytochrome P450 2C19 polymorphism on the metabolism of voriconazole in vitro
P2860
Q26823542-AAD16F8C-278E-4972-B61A-EF1159E68D12Q28362533-718A8E91-6A29-4DF4-8139-80747BBA96C1Q33290485-643E5A23-DD9E-422D-A21F-9F7CDF77CA32Q35057831-071E4ABC-3423-4955-A146-DD3998C55AA5Q35825569-1C36101A-C839-4599-8983-3E74E4EB3893Q35952367-74E709B9-83BF-4B46-B77B-6E9DC858B78DQ36053568-180CE9B5-A7BC-46C5-9537-C72A68F865C8Q36053911-2B8528E7-C043-4D1B-88E8-3F1538C7AF57Q36307008-B9673D14-6DF2-4019-BA79-85DD602DF231Q36475190-BD440261-D7E5-4540-B5D6-457771F9CA2AQ36580034-1E8F961C-5155-4487-B78A-E3484FF4FA09Q41595607-CE43D396-B2B6-46EB-A781-B91B612FC18CQ47554139-0014AADA-B70E-4A35-AF5C-F8D2D5F382B1Q59125874-1220C3E4-FBD8-42F5-8C3B-AA1ECD2B7105
P2860
Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin
description
1998 nî lūn-bûn
@nan
1998 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Identification of new human CY ...... oor metabolizer of mephenytoin
@ast
Identification of new human CY ...... oor metabolizer of mephenytoin
@en
Identification of new human CY ...... oor metabolizer of mephenytoin
@nl
type
label
Identification of new human CY ...... oor metabolizer of mephenytoin
@ast
Identification of new human CY ...... oor metabolizer of mephenytoin
@en
Identification of new human CY ...... oor metabolizer of mephenytoin
@nl
prefLabel
Identification of new human CY ...... oor metabolizer of mephenytoin
@ast
Identification of new human CY ...... oor metabolizer of mephenytoin
@en
Identification of new human CY ...... oor metabolizer of mephenytoin
@nl
P2093
P1476
Identification of new human CY ...... oor metabolizer of mephenytoin
@en
P2093
B I Ghanayem
C Bouchardy
G C Ibeanu
J A Goldstein
J Blaisdell
S Benhamou
P304
P407
P577
1998-09-01T00:00:00Z